IVAN data mined for insights on intravitreal anti-VEGF systemic safety
September 15th 2014Analyses of data from the Inhibition of VEGF in Age-related Choroidal Neovascularisation trial conducted to explore relationships between temporal changes in serum VEGF and safety events showed that at 1 year, a larger fall from baseline serum VEGF was associated with a lower hazard of death.
Lifestyle cooperative poised for growth as U.S. population ages
September 15th 2014The self-pay, lifestyle health care market is poised for huge growth as the population of the United States ages. A new cooperative offers a host of tools and services to help board-certified ophthalmologists capitalize on opportunities in the self-pay market.
DARPin delivers promising results in phase II study of exudative AMD:
September 15th 2014Abicipar pegol was at least as effective as ranibizumab for treatment of exudative age-related macular degeneration, and appeared to have a longer duration of action In a randomized, double-masked phase II study.
Aerie glaucoma eye drop treatment trial commences in Canada
September 9th 2014Dosing has commenced for the first patients enrolled in Aerie Pharmaceuticals’ phase III registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension.
Iluvien receives national marketing authorization in 10th country
September 9th 2014The Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Verteporfin does not improve efficacy of ranibizumab for AMD (VIDEO)
September 5th 2014William Fredette, MD, discusse the results of two trials published in Opthalmology, which indicate that the combination of Verteporfin Photodynamic Therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to AMD. Video provided by The Doctor's Channel.